BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Submission of Matters to a Vote of Security Holders

BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item 5.07, on May2, 2017, the shareholders of Bristol-Myers
Squibb Company (the Company) approved an amendment to the 2012
Stock Award and Incentive Plan (the Plan) at the annual meeting
of shareholders (the Annual Meeting). The material terms of the
Plan are summarized on pages72 through 79 of the Companys
definitive proxy statement on Schedule 14A filed with the
Securities and Exchange Commission on March23, 2017 (the Proxy
Statement), which description is incorporated by reference
herein. This description of the Plan is qualified in its entirety
by reference to the actual terms of the Plan, which are set forth
in ExhibitB to the Proxy Statement.

Item 5.07. Submission of Matters to a
Vote of Security Holders.

(a)The Annual Meeting of the Company was held on May2, 2017.

(b)Shareholders voted on the matters set forth below.

Item1. The shareholders elected each of the Companys 11
nominees to serve as directors of the Company until the 2018
Annual Meeting based upon the following votes:

Broker

For

Against

Abstain

Non-Vote

Peter J. Arduini

1,100,615,093

45,570,598

5,036,126

290,692,854

Robert J. Bertolini

1,109,816,316

36,472,897

4,932,604

290,692,854

Giovanni Caforio, M.D.

1,104,402,988

32,216,004

14,602,825

290,692,854

Matthew W. Emmens

1,136,617,381

9,705,394

4,899,042

290,692,854

Laurie H. Glimcher, M.D.

1,119,843,296

26,588,013

4,790,508

290,692,854

Michael Grobstein

1,102,275,978

43,991,784

4,954,055

290,692,854

Alan J. Lacy

1,102,695,889

43,445,194

5,080,734

290,692,854

Dinesh C. Paliwal

1,124,153,414

22,082,476

4,985,927

290,692,854

Theodore R. Samuels

1,114,430,970

31,954,143

4,836,704

290,692,854

Vicki L. Sato, Ph.D.

1,101,759,227

44,082,948

5,379,642

290,692,854

Gerald L. Storch

993,932,557

152,297,553

4,991,707

290,692,854

Item2. The management proposal on the advisory vote to
approve the compensation of our named executive officers was
approved based upon the following votes:

Broker

For

Against

Abstain

Non-Vote

1,103,113,789

39,019,098

9,088,930

290,692,854

Item3. The management proposal on the advisory vote of the
frequency of the advisory vote to approve the compensation of our
named executive officers was approved for one year based upon the
following votes:

Broker

One Year

Two Years

Three Years

Abstain

Non-Vote

1,044,153,592

4,730,559

96,169,015

6,168,651

290,692,854

Item 4. The management proposal on the re-approval of
the materials terms of the performance-based awards under the
Companys 2012 Stock Award and Incentive Plan (as amended) was
approved based upon the following votes:

Broker

For

Against

Abstain

Non-Vote

1,108,184,786

34,541,786

8,495,245

290,692,854

Item 5. The management proposal on an amendment to the
Companys 2012 Stock Award and Incentive Plan was approved based
upon the following votes:

Broker

For

Against

Abstain

Non-Vote

1,097,810,347

43,968,620

9,442,850

290,692,854

Item6. The appointment of Deloitte Touche LLP as
independent registered public accounting firm for the Company
for 2017 was ratified based upon the following votes:

For

Against

Abstain

1,375,692,222

59,215,717

7,006,732

Item 7. The shareholder proposal to lower the share
ownership threshold to call special shareholder meetings was
not approved based upon the following votes:

Broker

For

Against

Abstain

Non-Vote

437,525,037

704,934,045

8,762,735

290,692,854

(d)Based on the voting results set forth in (b)(3)above, the
companys Board of Directors has determined that an advisory
vote by the shareholders regarding named executive officer
compensation as set forth in the proxy statement will be
conducted on an annual basis.


About BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP)

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.

BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Recent Trading Information

BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) closed its last trading session up +0.50 at 940.00 with shares trading hands.

An ad to help with our costs